Anti-Rheumatic Rx
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
11 months 2 weeks ago
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.
The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
11 months 2 weeks ago
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
11 months 2 weeks ago
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
11 months 2 weeks ago
How do we improve MTX adherence?
Biochemical measure of MTX adherence
37% of patients starting a biologic do not take their MTX (!)
Those who do respond better to first Biologic at 6 Mo than those who don’t
37% biologic responders = non adherent
POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Rheumatoid Factor Lowering Predicts Improved Outcomes in RA. Abstract…
Podcasts
Don't You Know Who I Am (5.17.2024)-
My Cancelled Lecture (5.11.2024)
Roadblocks to reaching remission in lupus Sponsored by GSK US Medical Affairs
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1601919334745-0'); });
Poster Hall